A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients who are not able to take or have not gotten better after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Iclusig blocks BCR-ABL and other proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Also called ponatinib hydrochloride.